Δ9-Tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance

Life Sciences

Volumn 62, Issue 26, 1998, Pages 2431-2439

  Mallet, Paul E ^a   Beninger, Richard J ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

9 tetrahydrocannabinol; Anandamide; Cannabinoid; Place conditioning

Indexed keywords

ANANDAMIDE; BENZYLSULFONYL FLUORIDE; CANNABINOID RECEPTOR; DRONABINOL; LIGAND; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID; DRUG RECEPTOR; PROTEINASE INHIBITOR; PSYCHEDELIC AGENT; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONDITIONING; CONTROLLED STUDY; LOCOMOTION; MALE; NONHUMAN; RAT; ANIMAL; DRUG EFFECT; HALF LIFE TIME; MOTOR ACTIVITY; WISTAR RAT;

ANIMALIA; RATTUS NORVEGICUS;

ANIMALS; ARACHIDONIC ACIDS; AVOIDANCE LEARNING; CANNABINOIDS; HALF-LIFE; HALLUCINOGENS; MALE; MOTOR ACTIVITY; PHENYLMETHYLSULFONYL FLUORIDE; POLYUNSATURATED ALKAMIDES; PROTEASE INHIBITORS; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRAHYDROCANNABINOL;

EID: 0032557241     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00226-4     Document Type: Article

References (42)

1. 1. J.R. LEITE and E.A. CARLINI, Psychopharmacol. 36 133-145 (1974).
2. 2. M.E. CORCORAN and Z. AMIT, Psychopharmacol. 35 129-147 (1974).
3. 3. J.M. CARNEY, I.M. UWAYDAH and R.L. BALSTER, Pharmacol. Biochem. Behav. 7 357-364 (1977).
4. 4. R.S. MANSBACH, K.L. NICHOLSON, B.R. MARTIN and R.L. BALSTER, Behav. Pharmacol. 5 219-225 (1994).
5. 5. R.T. HARRIS, W. WATERS and D. MCLENDON, Psychopharmacol. 37 23-29 (1974).
6. 6. R.N. TAKAHASHI and G. SINGER, Pharmacol. Biochem. Behav. 11 737-740 (1979).
7. 7. P. STARK and P.B. DEWS, J. Pharmacol. Exp. Ther. 214 124-130 (1980).
8. 8. E.L. GARDNER, W. PAREDES, D. SMITH, A. DONNER, C. MILLING, D. COHEN and D. MORRISON, Psychopharmacol. 96 142-144 (1988).
9. 9. M.D. SCHECHTER and D.J. CALCAGNETTI, Neurosci. Biobehav. Rev. 17 21-41 (1993).
10. 10. L.A. PARKER and T. GILLIES, Behav. Neurosci. 109 71-78 (1995).
11. 11. M.C. SAÑUDO-PEÑA, K. TSOU, E.R. DELAY, A.G. HOHMAN, M. FORCE and J.M. WALKER, Neurosci. Lett. 223 125-128 (1997).
12. 12. M. LEPORE, S.R. VOREL, J. LOWINSON and E.L. GARDNER, Life Sci. 56 2073-2080 (1995).
13. 13. I.S. MCGREGOR, C.N. ISSAKIDIS and G. PRIOR, Pharmacol. Biochem. Behav. 53 657-664 (1996).
14. 14. W.A. DEVANE, L. HANUS, A. BREUER, R.G. PERTWEE, L.A. STEVENSON, G. GRIFFIN, D. GIBSON, A. MANDELBAUM, A. ETINGER and R. MECHOULAM, Science 258 1946-1949 (1992).
15. 15. C.C FELDER, A. NIELSEN, E.M. BRILEY, M. PALKOVITS, J. PRILLER, J. AXELROD, D.N. NGUYEN, J.M. RICHARDSON, R.M. RIGGIN, G.A. KOPPEL, S.M. PAUL and G.W. BECKER, FEBS Letters 393 231-235 (1997).
16. 16. K. MACKIE, W.A. DEVANE and B. HILLE, Molec. Pharmacol. 44 498-503 (1993).
17. 17. Z. VOGEL, J. BARG, R. LEVY, D. SAYA, E. HELDMAN and R. MECHOULAM, J. Neurochem. 61 352-355 (1993).
18. 18. E. FRIDE and R. MECHOULAM, Eur. J. Pharmacol. 231 313-314 (1993).
19. 19. J.N. CRAWLEY, R.L. CORWIN, J.K. ROBINSON, C.C. FELDER, W.A. DEVANE and J. AXELROD, Pharmacol. Biochem. Behav. 46 967-972 (1993).
20. 20. P.B. SMITH, D.R. COMPTON, S.P. WELCH, R.K. RAZDAN, R. MECHOULAM and B.R. MARTIN, J. Pharmacol. Exp. Ther. 270 219-227 (1994).
21. 21. J. ROMERO, L. GARCÍA, M. CEBEIRA, D. ZADROZNY, J.J. FERNÁNDEZ-RUIZ and J.A. RAMOS, Life Sci. 56 2033-2040 (1995).
22. 22. P.E. MALLET and R.J. BENINGER, Behav. Pharmacol. 7 276-284 (1996).
23. 23. D.G. DEUTSCH and S.A. CHIN, Biochem. Pharmacol. 46 791-796 (1993).
24. 24. R.G. PERTWEE, S.R. FERNANDO, G. GRIFFIN, V. ABADJI and A. MAKRIYANNIS, Eur. J. Pharmacol. 272 73-78 (1995).
25. 25. V. ABADJI, S. LIN, G. TAHA, G. GRIFFIN, L.A. STEVENSON, R.G. PERTWEE and A. MAKRIYANNIS, J. Med. Chem. 37 1889-1893 (1994).
26. 26. N.T. BROCKWELL, D.S. FERGUSON and R.J. BENINGER, J. Neurosci. Meth. 64 227-232 (1996).
27. 27. D.C. HOFFMAN and R.J. BENINGER, Pharmacol. Biochem. Behav. 33 273-279 (1989).
28. 28. S. MITHANI, M.T. MARTIN-IVERSON, A.G. PHILLIPS and H.C. FIBIGER, Psychopharmacol. 90 247-252 (1986).
29. 29. G.E.P. BOX, Ann. Math. Stat. 25 484-498 (1954).
30. 30. G. KEPPEL. Design and analysis: A researcher's handbook, p.23, Prentice Hall, Englewood Cliffs, NJ (1991).
31. 31. J. CHEN, W. PAREDES, J. LI, D. SMITH, J. LOWINSON and E.L. GARDNER, Psychopharmacol. 102 156-162 (1990).
32. 32. E. CASTAÑEDA, D.E. MOSS, S.D. ODDIE and I.Q. WISHAW, Pharmacol. Biochem. Behav. 40 587-591 (1991).
33. 33. L.L. MILLER and R.J. BRANCONNIER, Psychol. Bull. 93 441-456 (1983).
34. 34. M. DEAHL, Br. J. Addict. 86 249-252 (1991).
35. 35. E.J. ESSMAN, Psychol. Bull. 55 563-567 (1984).
36. 36. T.G. AIGNER, Psychopharmacol. 95 507-511 (1988).
37. 37. E.M. NAKAMURA, E.A. DA SILVA, G.V. CONCILIO, D.A. WILKINSON and J. MASUR, Drug Alcohol Dep. 28 167-175 (1991).
38. 38. C.J. HEYSER, R.E. HAMPSON and S.A. DEADWYLER, J. Pharmacol. Exp. Ther. 264 294-307 (1993).
39. 39. P.E. MALLET and R.J. BENINGER, Soc. Neurosci. Abstr. 23 2382 (1997).
40. 40. T.H. BURKEY, R.M. QUOCK, P. CONSROE, W.R. ROESKE and H.I. YAMAMURA, Eur. J. Pharmacol. 323 R3-R4 (1997).
41. 41. L.J. SIM, R.E. HAMPSON, S.A. DEADWYLER and S.R. CHILDERS, J. Neurosci. 16 8057-8066 (1996).
42. 42. E.S. ONAIVI, M.R. GREEN and B.R. MARTIN, J. Pharmacol. Exp. Ther. 253 1002-1009 (1990).